Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02061813
Other study ID # Ha03-007
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date January 2014
Est. completion date May 2014

Study information

Verified date July 2021
Source Dr. Reddy's Laboratories Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to determine the irritation potential of repeat applications of abametapir lotion on normal skin.


Description:

This will be a randomized, evaluator-blind, single-center, controlled, within-subject comparison study of the investigational products (abametapir lotion) and its vehicle lotion and positive and negative controls under occlusive conditions in healthy volunteers. All subjects will have the investigational product (abametapir lotion), the vehicle product, the positive control patch, and negative control patch applied to 4 randomly assigned, adjacent skin sites on the infrascapular area of their back, for the purpose of determining irritation potential. The investigational products, vehicle, and controls will be applied to one side of the infrascapular area of the back. Evaluation of dermal reactions at the application sites will be assessed clinically using a visual scale that rates the degree of erythema, edema, and other signs of cutaneous irritation (see Section 3.5.5). A total of 21 applications of each product will be made.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date May 2014
Est. primary completion date January 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Are healthy (to be confirmed by medical history) males or females, 18 years of age or older; 2. In the case of females of childbearing potential, are using an acceptable form of birth control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom with spermicide, diaphragm with spermicide, abstinence, partner's vasectomy). Abstinence or vasectomized partner are acceptable if the female subject agrees to implement one of the other acceptable methods of birth control if her lifestyle/partner changes; 3. If female of childbearing potential, have a negative urine pregnancy test (UPT) at Day 1, and are willing to submit to a pregnancy test at the end of study (EOS); 4. Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events; 5. Are of any skin type or race, providing the skin pigmentation will allow discernment of erythema; 6. Complete a patch study Medical Screening form as well as a Medical Personal History form; and 7. Read, understand, and provide signed informed consent. Exclusion Criteria: 1. Have any visible skin disease at the application site which, in the opinion of the investigative personnel, will interfere with the evaluation of the test site reaction; 2. Are not willing to refrain from using topical/systemic analgesics such as aspirin (daily use of 81 mg aspirin is acceptable), Aleve, Motrin, Advil, or Nuprin for 72 hours prior to and during the study (occasional use of acetaminophen will be permitted); 3. Are using inhaled/systemic/topical corticosteroids in the 3 weeks prior to and during the study, or systemic/topical antihistamines for 72 hours prior to and during the study; 4. Are using medication which, in the opinion of the investigative personnel, will interfere with the study results, including anti-inflammatory medications; 5. Are unwilling or unable to refrain from the use of sunscreens, cosmetics, creams, ointments, lotions, or similar products on the back during the study; 6. Have psoriasis and/or active atopic dermatitis/eczema; 7. Are females who are pregnant, plan to become pregnant during the study, or are breast-feeding a child; 8. Have a known sensitivity to constituents present in the material being evaluated; 9. Have damaged skin in or around the test sites, including sunburn, excessively deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfigurations of the test site 10. Have received treatment for any type of internal cancer within 5 years prior to study entry; 11. Have a history of, or are currently being treated for skin cancer; 12. Are currently participating in any other clinical trial, 13. Have any known sensitivity to adhesives; and/or 14. Have received any investigational treatment(s) within 4 weeks prior to study entry.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Abametapir Lotion 0.74% w/w
applied 0.2 mL topically under occlusive condition
Sodium Lauryl Sulfate
Sodium Lauryl Sulfate is prepared as a 0.2% aqueous solution by the site for topical administration, and applied 21 times over consecutive days under occlusive conditions, will serve as a positive control.
Saline 0.9%
A solution of 0.9% saline for topical administration, applied 21 times over consecutive days under occlusive conditions, will serve as a negative control
Placebo


Locations

Country Name City State
United States TKL Reserach Inc Paramus New Jersey

Sponsors (1)

Lead Sponsor Collaborator
Dr. Reddy's Laboratories Limited

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Potential of Abametapir Lotion to Cause Irritation After Repeated Topical Application to the Healthy Skin of Humans. The evaluation of irritation is based on Modified Berger procedure and is accepted as standard methodology for assessment of cumulative irritation potential. The assessment of all patch sites for irritation symptoms will be visually assessed by a trained evaluator using the numerical equivalents (0-7) where 0 is the least irritation potential and 7 is the maximum irritation potential. The scoring will be done on daily basis from baseline through Day 21 visit. The final reported outcome is a mean of the scores over 21 days. 21 days
See also
  Status Clinical Trial Phase
Completed NCT00988533 - A Pharmacokinetics (PK) Study in Lice Infested Children 6 Months to 3 Years of Age Phase 1
Completed NCT00672971 - Safety and Efficacy Study to Compare a 4% Dimethicone Foam and Nix Cream Rinse (1% Permethrin) in the Control of Head Lice N/A
Completed NCT00858481 - A Pilot Dose Ranging Study of Spinosad Creme Rinse Phase 2
Completed NCT03301649 - Clinical Endpoint Study of Ivermectin 0.5% Lotion Phase 3
Completed NCT00994422 - Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects Phase 2
Completed NCT00995124 - Trial of the Ovicidal Activity of Three Head Lice Products (NeutraLice Lotion®, NeutraLice Advance® and Moov Head Lice Solution®) After a Single Application Phase 4
Completed NCT03337490 - A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice Phase 3
Completed NCT06333054 - Safety and Efficacy of a Head Lice Shampoo N/A
Completed NCT02213055 - Pediatric Head Lice Study Product Comparison Phase 2
Completed NCT02974088 - Neem Lotion With Combing for Lice Phase 2
Recruiting NCT05379114 - Comparative Study for the Evaluation of a New Medical Device on the Treatment of Head Lice Infestation N/A
Completed NCT03617926 - A Clinical Trial to Evaluate Efficacy and Safety of a Water-soluble Head Lice Product. N/A
Completed NCT01803581 - A Study to Evaluate the Safety and Efficacy of Product X92001327 vs RID Shampoo in Subjects With Head Lice N/A
Completed NCT01066585 - A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation Phase 3
Completed NCT01068158 - A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects Phase 3
Completed NCT00857935 - A Safety and Efficacy Pilot Study Comparing NatrOVA Creme Rinse 1% and NIX Creme Rinse Phase 2
Completed NCT00301340 - Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.)for the Treatment of Head Lice Phase 3
Completed NCT02062073 - Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion Phase 1
Completed NCT00605956 - NatrOVA Photoallergy Study - NatrOVA Creme Rinse in Healthy Volunteers Phase 1
Completed NCT00301327 - Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.)for the Treatment of Head Lice. Phase 3